Loading…
Humacyte, Inc. is projected to decline to $1.06 by 2027, a -8% move from its current price of $1.15. HUMA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.07 | $1.15 | $1.23 | -0.04% |
| May 30 | $1.04 | $1.15 | $1.26 | -0.07% |
| May 31 | $1.02 | $1.15 | $1.29 | -0.11% |
| Jun 1 | $1.00 | $1.15 | $1.31 | -0.15% |
| Jun 2 | $0.9872 | $1.15 | $1.33 | -0.18% |
| Jun 3 | $0.9727 | $1.15 | $1.35 | -0.22% |
| Jun 4 | $0.9596 | $1.15 | $1.37 | -0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9596 | $1.15 | $1.37 | -0.25% |
| Week 2 | $0.889 | $1.14 | $1.47 | -0.51% |
| Week 3 | $0.8378 | $1.14 | $1.55 | -0.76% |
| Week 4 | $0.7966 | $1.14 | $1.63 | -1.02% |
| Week 5 | $0.7618 | $1.14 | $1.69 | -1.27% |
| Week 6 | $0.7315 | $1.13 | $1.75 | -1.52% |
| Week 7 | $0.7045 | $1.13 | $1.81 | -1.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Humacyte, Inc. is a healthcare company that develops and manufactures off-the-shelf, implantable, and bioengineered human tissues for use across a range of anatomic locations and therapeutic areas. The company uses its proprietary technology platform to engineer and manufacture human acellular vessels (HAVs) intended for implantation without provoking a foreign body response or immune rejection.
Founded in 2004, Humacyte is headquartered in Durham, North Carolina. The business focuses on vascular repair, reconstruction, and replacement markets, including vascular trauma, arteriovenous access for hemodialysis, peripheral arterial disease, pediatric heart surgery, and coronary artery bypass grafting, as well as for cellular therapy delivery such as pancreatic islet cell transplantation for Type 1 diabetes.
Humacyte, Inc. (HUMA) currently trades at $1.15 per share and has a market capitalization of $255.32M, with a market ranking of 3611. The stock’s price action is supported by a bullish tilt in the near term, while the longer-term forecast shows a pathway of growth with year-by-year variance.
The forecast notes a 2026 average price of $1.15, and a path toward higher averages in later years, culminating in a 2030 average of $1.52 and a 2050 average of $4.71, with a potential max of $10.83. The implied volatility remains high at 100%, underscoring the elevated risk and potential upside embedded in the long horizon. Overall, the asset presents a mixed near-term picture with a longer-term bullish trajectory indicated by the forecast, though early years exhibit flat or negative ROI before expanding meaningfully in the 2030s and beyond.
A major floor 56.9% below — a decisive break under it would weaken the trend.
The nearest floor, 42.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 28.5% above — clearing it would confirm fresh momentum.
Key HUMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HUMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.05 | Buy | $1.07 | Buy |
| MA 10 | $1.00 | Buy | $1.02 | Buy |
| MA 20 | $0.9703 | Buy | $0.9639 | Buy |
| MA 50 | $0.8273 | Buy | $0.92 | Buy |
| MA 100 | $0.9582 | Buy | $1.00 | Buy |
| MA 200 | $1.22 | Sell | $1.34 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.65 | Neutral |
| Stoch RSI (14) | 66.75 | Neutral |
| CCI (20) | 136.18 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 8.49 | Buy |
| Bollinger %B (20,2) | 0.95 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.95 | Buy |
| Awesome (5,34) | 0.19 | Buy |
| Ultimate (7,14,28) | 68.79 | Neutral |
| Momentum (10) | 0.24 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 1.13 | Buy |
| ADX (14) | 17.28 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture shows bullish sentiment with an RSI of 60 and a price trend above a tight trading range. The 50-day simple moving average sits at $0.8273, while the 200-day simple moving average is at $1.22, signaling a potential transition in momentum as price tests resistance. Key support sits at $0.659 and a resistance at $1.15, framing a 30-day range from $0.7372 to $1.79.
The combination of elevated volatility and the near-term range suggests a watchful stance on price movement over the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.575 | $1.15 | $1.50 | 0% | Neutral | |
| $0.7653 | $1.06 | $1.60 | -8% | Neutral | |
| $0.7097 | $1.05 | $1.67 | -9% | Neutral | |
| $0.6338 | $0.9838 | $1.65 | -14% | Neutral | |
| $0.9375 | $1.52 | $2.66 | +33% | Bullish | |
| $1.02 | $1.74 | $3.14 | +51% | Bullish | |
| $0.8692 | $1.54 | $2.86 | +34% | Bullish | |
| $0.8542 | $1.58 | $3.01 | +37% | Bullish | |
| $0.7896 | $1.52 | $2.97 | +32% | Bullish | |
| $0.8113 | $1.62 | $3.24 | +41% | Bullish | |
| $0.9287 | $2.06 | $4.54 | +79% | Bullish | |
| $2.12 | $4.71 | $10.83 | +309% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.575 | $1.15 | $1.35 | +0.00% |
| June 2026 | $0.9094 | $1.09 | $1.36 | -5.16% |
| July 2026 | $0.912 | $1.11 | $1.42 | +2.00% |
| August 2026 | $0.8698 | $1.08 | $1.40 | -3.35% |
| September 2026 | $0.8134 | $1.02 | $1.34 | -5.45% |
| October 2026 | $0.8402 | $1.06 | $1.42 | +4.36% |
| November 2026 | $0.8814 | $1.12 | $1.52 | +5.86% |
| December 2026 | $0.8515 | $1.09 | $1.50 | -2.55% |
Click any year to see its month-by-month HUMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The HUMA price prediction for 2026 points to an average of $1.15 (low $0.575, high $1.50) — a potential gain of 0% on today's $1.15. Price action looks broadly range-bound.
In 2027, HUMA is projected to trade between $0.7653 and $1.60, averaging $1.06 — a potential decline of -8% from today's $1.15. That is -8% versus the projected 2026 average. A consolidation phase looks the most probable path here.
Humacyte, Inc.'s 2028 outlook centres on $1.05, within a $0.7097 to $1.67 range. That is -2% versus the projected 2027 average. That marks a -9% change versus current levels. Price action looks broadly range-bound.
By 2029, HUMA could reach as high as $1.65, with a base case around $0.9838 and support toward $0.6338 — roughly -14% from $1.15. A consolidation phase looks the most probable path here.
Expect HUMA to range from $0.9375 to $2.66 through 2030. The $1.52 average target implies a +33% move from current prices. That is up +55% on the projected 2029 average. Momentum favours further upside here.
The HUMA price prediction for 2031 points to an average of $1.74 (low $1.02, high $3.14) — a potential gain of +51% on today's $1.15. Buyers look set to stay in control over this stretch.
In 2032, HUMA is projected to trade between $0.8692 and $2.86, averaging $1.54 — a potential gain of +34% from today's $1.15. That is -11% versus the projected 2031 average. Momentum favours further upside here.
Humacyte, Inc.'s 2033 outlook centres on $1.58, within a $0.8542 to $3.01 range. That is up +2% on the projected 2032 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, HUMA could reach as high as $2.97, with a base case around $1.52 and support toward $0.7896 — roughly +32% from $1.15. Momentum favours further upside here.
Expect HUMA to range from $0.8113 to $3.24 through 2035. The $1.62 average target implies a +41% move from current prices. That is up +7% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The HUMA price prediction for 2040 points to an average of $2.06 (low $0.9287, high $4.54) — a potential gain of +79% on today's $1.15. Momentum favours further upside here.
In 2050, HUMA is projected to trade between $2.12 and $10.83, averaging $4.71 — a potential gain of +309% from today's $1.15. That is up +128% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in HUMA today (≈ 869.565217 HUMA) could be worth
$4,093.96
+$3,093.96 (+309%) by 2050 · US Dollar
Based on the average projected HUMA price of $4.71 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HUMAwould be worth at today's price.
$1,000 invested in HUMA on May 27, 2025 (≈ 403.225803 HUMA) would be worth
$463.71
-$536.29 (-53.6%) today · 0.46× · US Dollar
Based on a HUMA entry price of $2.48 vs. today's $1.15.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.917 | $1,254.09 | +25.4% |
| 1 month ago | $0.806 | $1,426.8 | +42.7% |
| 3 months ago | $1.23 | $934.96 | -6.5% |
| 6 months ago | $1.35 | $851.85 | -14.8% |
| 1 year ago | $2.48 | $463.71 | -53.6% |
| All time (5.0y) ago | $9.97 | $115.35 | -88.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HUMA forecast.
Our base-case forecast reaches $2.30 around 2050.
Implied market cap at $2.30: $510.64M
The multi-year forecast paints a progressive rise in average prices from 2026 onward, with a neutral stance in 2026 and gradual bullish momentum thereafter. In 2030, the avg is $1.52 with a 32.6% ROI and a bullish sentiment. The sequence continues with 2031 at $1.74 avg (51.3% ROI) and 2032 at $1.54 avg (34% ROI), followed by 2033 at $1.58 avg (37.1% ROI) and 2034 at $1.52 avg (31.8% ROI).
By 2035 the avg sits at $1.62 with a 40.7% ROI. The forecast accelerates into the 2040s, with 2040 avg $2.06 and a 79.5% ROI, reflecting a meaningful upside. By 2050, the avg price is projected at $4.71 with a max of $10.83 and a 309.4% ROI, signaling the strongest long-term upside in the horizon.
These figures provide a directional sense of potential appreciation, but they come with inherent uncertainty and do not guarantee future results. Risks noted include early-year negative ROI around 2027–2029 and the general caveat that forecasts are estimates subject to change as market and company fundamentals evolve.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $1.52, a max of $2.66, and a 32.6% ROI with bullish sentiment.
The long-term view is bullish from 2030 onward with higher expected averages and positive ROIs, but the early years (2027–2029) show negative ROIs and the forecast carries uncertainty and risk.
Yes—the 2050 forecast lists a max of $10.83, indicating potential upside in the long term.
Current price is $1.15 and market cap is $255.32M.
The 30-day range is from $0.7372 to $1.79, with a near-term resistance at $1.15 and support at $0.659.
Humacyte, Inc. Community Discussion
0Share your Humacyte, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.